Cargando…

Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves

Provision of an adequate mass of IgG from maternal colostrum is essential to health and survival of neonatal calves. Colostrum supplements (CS) have been developed to provide supplemental immunoglobulin when maternal colostrum is of poor quality. However, colostrum replacers (CR) that provide ≥100 g...

Descripción completa

Detalles Bibliográficos
Autores principales: Quigley, J.D., Strohbehn, R.E., Kost, C.J., O’Brien, M.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Dairy Science Association. Published by Elsevier Inc. 2001
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157919/
https://www.ncbi.nlm.nih.gov/pubmed/11573786
http://dx.doi.org/10.3168/jds.S0022-0302(01)74650-4
_version_ 1783522436488101888
author Quigley, J.D.
Strohbehn, R.E.
Kost, C.J.
O’Brien, M.M.
author_facet Quigley, J.D.
Strohbehn, R.E.
Kost, C.J.
O’Brien, M.M.
author_sort Quigley, J.D.
collection PubMed
description Provision of an adequate mass of IgG from maternal colostrum is essential to health and survival of neonatal calves. Colostrum supplements (CS) have been developed to provide supplemental immunoglobulin when maternal colostrum is of poor quality. However, colostrum replacers (CR) that provide ≥100 g of IgG have not been formulated. Our objective was to determine the absorption of IgG in newborn calves fed CS derived from bovine serum or CR derived from bovine immunoglobulin concentrate. The CS were prepared by collecting, processing, and spray drying bovine serum and blending with other ingredients to provide 45 to 50 g of IgG per dose. The CR were prepared by further processing bovine serum to increase IgG concentration to >50% IgG and blending with other ingredients to provide 100 to 122 g of IgG per dose. Holstein calves (n = 160) were fed 90 to 244 g of IgG from CS or CR in 1 or 2 feedings in two experiments. Blood was collected from each calf by jugular venipuncture at 0 and 24 h of age and plasma IgG was determined by turbidimetric immunoassay. Apparent efficiency of IgG absorption was calculated. Plasma IgG concentrations at 24 h of age were indicative of IgG intake and averaged 5.5 to 14.1 g/L in calves fed CS and CR. Mean apparent efficiency of IgG absorption in calves fed CS was 25 and 28% in experiments 1 and 2, respectively. Mean apparent efficiency of IgG absorption in calves fed CR ranged from 19 to 32% and were affected by method of processing and number of times fed. Treatment of plasma with polyethylene glycol reduced the efficiency of IgG absorption in experiment 1. The addition of animal fat to CR had no effect on IgG absorption. A second feeding of CR increased plasma IgG, but efficiency of absorption was reduced. Mean body weights at 60 d of age were not affected by treatment and ranged from 64.3 to 78.2 kg. Plasma IgG concentration in calves fed ≥122 g of IgG from Ig concentrate approached (9.9 g/L) or exceeded 10 g/L, indicating successful transfer of passive immunity. Provision of IgG to prevent failure of passive transfer is possible with CR containing >20% IgG when fed at 454 g per dose.
format Online
Article
Text
id pubmed-7157919
institution National Center for Biotechnology Information
language English
publishDate 2001
publisher American Dairy Science Association. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-71579192020-04-15 Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves Quigley, J.D. Strohbehn, R.E. Kost, C.J. O’Brien, M.M. J Dairy Sci Article Provision of an adequate mass of IgG from maternal colostrum is essential to health and survival of neonatal calves. Colostrum supplements (CS) have been developed to provide supplemental immunoglobulin when maternal colostrum is of poor quality. However, colostrum replacers (CR) that provide ≥100 g of IgG have not been formulated. Our objective was to determine the absorption of IgG in newborn calves fed CS derived from bovine serum or CR derived from bovine immunoglobulin concentrate. The CS were prepared by collecting, processing, and spray drying bovine serum and blending with other ingredients to provide 45 to 50 g of IgG per dose. The CR were prepared by further processing bovine serum to increase IgG concentration to >50% IgG and blending with other ingredients to provide 100 to 122 g of IgG per dose. Holstein calves (n = 160) were fed 90 to 244 g of IgG from CS or CR in 1 or 2 feedings in two experiments. Blood was collected from each calf by jugular venipuncture at 0 and 24 h of age and plasma IgG was determined by turbidimetric immunoassay. Apparent efficiency of IgG absorption was calculated. Plasma IgG concentrations at 24 h of age were indicative of IgG intake and averaged 5.5 to 14.1 g/L in calves fed CS and CR. Mean apparent efficiency of IgG absorption in calves fed CS was 25 and 28% in experiments 1 and 2, respectively. Mean apparent efficiency of IgG absorption in calves fed CR ranged from 19 to 32% and were affected by method of processing and number of times fed. Treatment of plasma with polyethylene glycol reduced the efficiency of IgG absorption in experiment 1. The addition of animal fat to CR had no effect on IgG absorption. A second feeding of CR increased plasma IgG, but efficiency of absorption was reduced. Mean body weights at 60 d of age were not affected by treatment and ranged from 64.3 to 78.2 kg. Plasma IgG concentration in calves fed ≥122 g of IgG from Ig concentrate approached (9.9 g/L) or exceeded 10 g/L, indicating successful transfer of passive immunity. Provision of IgG to prevent failure of passive transfer is possible with CR containing >20% IgG when fed at 454 g per dose. American Dairy Science Association. Published by Elsevier Inc. 2001-09 2010-04-02 /pmc/articles/PMC7157919/ /pubmed/11573786 http://dx.doi.org/10.3168/jds.S0022-0302(01)74650-4 Text en Copyright © 2001 American Dairy Science Association. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Quigley, J.D.
Strohbehn, R.E.
Kost, C.J.
O’Brien, M.M.
Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves
title Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves
title_full Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves
title_fullStr Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves
title_full_unstemmed Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves
title_short Formulation of Colostrum Supplements, Colostrum Replacers and Acquisition of Passive Immunity in Neonatal Calves
title_sort formulation of colostrum supplements, colostrum replacers and acquisition of passive immunity in neonatal calves
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7157919/
https://www.ncbi.nlm.nih.gov/pubmed/11573786
http://dx.doi.org/10.3168/jds.S0022-0302(01)74650-4
work_keys_str_mv AT quigleyjd formulationofcolostrumsupplementscolostrumreplacersandacquisitionofpassiveimmunityinneonatalcalves
AT strohbehnre formulationofcolostrumsupplementscolostrumreplacersandacquisitionofpassiveimmunityinneonatalcalves
AT kostcj formulationofcolostrumsupplementscolostrumreplacersandacquisitionofpassiveimmunityinneonatalcalves
AT obrienmm formulationofcolostrumsupplementscolostrumreplacersandacquisitionofpassiveimmunityinneonatalcalves